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Introduction
Polycystic ovary syndrome (PCOS) is one of the 
commonest female endocrinopathies. PCOS is a highly 
prevalent disorder affecting about 6-10% of women of 
reproductive age [1-3] and has long-term fallout that 
goes beyond reproductive age [4]. Its aetiopathogenesis 
is complex, multifactorial, and heterogeneous, includ-
ing the interaction of genetic, epigenetic, and environ-
mental factors [5]. The common clinical manifestations 
of this syndrome are oligo-anovulation, hyperandro-
genism, and/or hyperandrogenaemia and polycys-
tic ovary morphology [2, 6, 7]. PCOS is established as 
a  metabolic disorder [6]. Cardiovascular risk factors 
such as hypertension, dyslipidaemia, metabolic syn-
drome, and obesity are more frequent among women 
with PCOS compared to non-PCOS women [6, 9]. This 
has led to the assumption that women with PCOS have 
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a higher risk of developing cardiovascular diseases in 
later life [6, 10, 11].
There are limited studies about cardiovascular dis-
orders, especially hypertension, in postmenopausal 
women with a history of PCOS. Most authors suggest 
that PCOS in postmenopausal women increases the 
risk of hypertension with all its consequences.
Material and methods
The authors searched the PubMed database with 
different combinations of the key words: “polycystic 
ovary syndrome”, “menopause”, “blood pressure”, 
and “hypertension”. The established inclusion criteria 
for the following review were: an original prospective, 
cross-sectional or retrospective study with at least five 
years of follow-up, and a study group of at least 30 par-
ticipants. Only six trials met the inclusion criteria. All of 
them are summarised in Table 1.
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Results
Schmidt et al. carried out long-term, prospective 
follow-up research of 35 postmenopausal women with 
PCOS and 120 age-matched controls. The population 
participated in a study in 1987 and was reinvestigated 
21 years later. The aim of their study was to examine 
whether postmenopausal PCOS women differ from the 
control group with regard to cardiovascular risk fac-
tors, myocardial infarction, stroke, and mortality. They 
studied parameters such as blood pressure, insulin, 
triglycerides, total cholesterol, and fibrinogen as well 
as incidences of myocardial infarction, stroke, hyper-
tension, and diabetes. They found that menopausal 
patients with PCOS had a higher prevalence of hyper-
tension and higher triglyceride levels than controls. The 
well-described cardiovascular profile in pre- and peri-
menopausal PCOS women does not entail an evident 
increase in cardiovascular events during the postmeno-
pausal period [12].
Armeni et al. conducted a study to evaluate the ef-
fect of PCOS on markers of subclinical atherosclerosis in 
nondiabetic postmenopausal women. They examined 
blood pressure, blood samples, and arterial structure 
(intima-media thickness, atheromatous plaque pres-
ence) and function (flow-mediated dilation, pulse wave 
velocity, augmentation index) by ultrasound. They ob-
tained similar results to Schmidt’s study. Armeni et al. 
ascertained that postmenopausal women with PCOS 
had higher systolic blood pressure and triglycerides and 
lower high-density lipoprotein (HDL) cholesterol than 
controls. The values of pulse wave velocity differed 
significantly between PCOS participants and controls. 
According to the authors, arterial stiffness is increased 
in asymptomatic, nondiabetic women with PCOS inde-
pendently of age, BMI, or blood pressure [13].
Another study, carried out in PCOS women of repro-
ductive age, gave evidence that the insulin resistance 
of arterial endothelial cells is associated with reduced 
synthesis of nitric oxide and increased synthesis of va-
soconstricting agents. This leads to increased vascular 
stiffness and consequent hypertension. The authors 
also found elevated levels of tissue plasminogen acti-
vator in such patients, which correlated with body mass 
index (BMI) and insulin resistance [14].
Elting et al. investigated the prevalence of diabetes 
mellitus, hypertension, and cardiac diseases in a Dutch 
population with PCOS, comparing these conditions in 
the healthy Dutch female population. In PCOS women 
aged 45-54 years (n = 32) the prevalence of hyperten-
sion was 2.5 times higher than the corresponding age 
group of the Dutch female population. The strongest 
predictor of hypertension was elevated BMI [15].
Wild et al. conducted a retrospective study of wom-
en diagnosed with PCOS an average of 31 years pre-
viously and found an increased prevalence of hyper-
tension compared to a cohort of control women [16]. 
Dahlgren et al. studied if the hormonal imbalance in 
women with polycystic ovary syndrome continues into 
and after menopause and analysed factors constituting 
an increased risk for developing metabolic disorders. 
Blood pressure was examined in menopausal women 
with PCOS, who had undergone ovarian wedge resec-
tion. It was a  long-term follow-up study that showed 
that menopausal women post ovarian wedge resection 
were three times more likely to have hypertension com-
pared to non-PCOS women [17].
Most of the available literature data suggest an 
increased prevalence of elevated blood pressure in 
Table 1. Studies on cardiovascular disease risk in women with polycystic ovarian syndrome (PCOS)
Study Type of study PCOS  
vs. control (n)
Mean or median age 
at follow-up (years)
Conclusions
Dahlgren [17]
1992
Cross-sectional 33 vs. 132 40-59 Perimenopausal women with PCOS have increased 
morbidity in hypertension and diabetes mellitus
Wild [16]
2000
Retrospective 319 vs. 1060 56.7 (31 years  
follow up)
Increased prevalence of hypertension in 
menopausal-PCOS women compared to a cohort 
of control women
Elting [15]
2001
Retrospective 32 vs. 2372 45-54 2.5-times higher prevalence of hypertension than 
the corresponding age group of the Dutch female 
population
Schmidt [12]
2011
Cross-sectional 32 vs. 120 61-79
(after 21 years  
of follow up)
High prevalence of hypertension and high 
triglyceride levels in postmenopausal PCOS 
women
Armeni [13]
2013
Cross-sectional 43 vs. 286 55.6 ±7.8 Higher systolic blood pressure and triglycerides 
and lower high-density
lipoprotein (HDL) cholesterol than controls
Merz [20]
2016
Cross-sectional 25 vs. 270 62.6 ±11.6 Clinical features of PCOS were not a significant 
predictor in prognostic models including 
hypertension, diabetes, waist circumference,  
and angiographic coronary artery disease
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women with PCOS compared to the healthy population. 
However, obesity is also a factor complicating the inter-
pretation of these studies, as a well-known risk factor 
for hypertension [18].
Dalmasso et al. tried to ascertain whether chronic 
hyperandrogenaemia would result in a  more harmful 
effect on metabolic function, blood pressure, and renal 
function than normo-androgenaemic age-matched fe-
males. They applied an animal model using rats. Female 
rats were implanted with dihydrotestosterone and were 
studied at 13 months. In this group it was observed that 
their blood pressure was significantly higher, heart rate 
was lower, and renal function (GFR) was reduced by 
40%. They also observed that insulin resistance was 
more significant in rats with higher plasma insulin, nor-
mal fasting blood glucose, abnormal oral glucose toler-
ance test, and higher non-fasting blood glucose. Thus, 
the chronically hyperandrogenic female rat is a model 
of postmenopausal PCOS, which exhibits insulin resis-
tance and visceral obesity, hypertension, and debility in 
renal function [19].
On the other hand, Merz et al. claimed that clini-
cal features of PCOS were not significant predictors in 
prognostic models for hypertension, diabetes, waist cir-
cumference, and angiographic coronary artery disease. 
However, these data should be interpreted with caution 
because of the small cohort of participants (295 post-
menopausal women, only 25% with clinical features of 
PCOS defined by a premenopausal history of irregular 
menses and current biochemical evidence of hyperan-
drogenaemia). Their findings question whether identi-
fication of clinical features of PCOS in postmenopausal 
women who already have known cardiovascular dis-
ease provides any additional opportunity for risk factor 
intervention [20].
Discussion
Why are postmenopausal women with a history of 
PCOS more prone to develop hypertension compared to 
postmenopausal non-PCOS women? 
Generally, long-term risk of cardiovascular com-
plications has been linked to an increase in oxidative 
stress and inflammatory markers.
Some studies have shown that in women with PCOS 
endothelial dysfunction goes together with, and is in-
fluenced by, the presence of increased serum levels of 
cytokines and endothelial activation markers. These 
parameters appear to be correlated with hyperandro-
genaemia in this insulin-resistant population [21].
Endothelial dysfunction is the starting point of de-
veloping cardiovascular disease [22].
Hypertension develops because of decreased vascu-
lar compliance and endothelial dysfunction in women 
with PCOS [23]. Endothelial dysfunction is proportional 
to the level of androgens and insulin resistance [21]. 
Hyperinsulinaemia influences the hypertrophic effect 
on vascular endothelial and smooth muscle cells; it also 
advocates endothelin 1 (ET-1) production [23]. ET-1 is 
a vasoactive substance involved in regulating endothe-
lial function, which is commonly chronically increased in 
women with PCOS. ET-1 is a product of oxidative stress 
and also a marker of endothelial dysfunction [24].
It has also been proven that androgens may influ-
ence microcirculatory regulation with effects on both 
vascular smooth muscle and the endothelium through 
actions on substances in the blood such as endothelin 1 
[24].
Moreover, intensification of expression of sICAM-1 
and sVCAM-1 molecules was observed in PCOS women, 
which play an important role in focal leukocyte accumu-
lation in subendothelial regions of atheroma [21, 25]. 
In addition, there is correlation between sVCAM-1 and 
hyperandrogenaemia. High testosterone levels have 
been found to induce VCAM expression. Androgens 
might promote monocyte adhesion to endothelial cells 
in the development of atherosclerosis [25]. A  proath-
erogenic process might be indicated in PCOS-women 
by extended CRP levels – another cardiovascular risk 
factor – and endothelial dysfunction [26]. Data suggest 
that increased levels of CRP are consistent with the se-
verity of endothelial dysfunction, which supports the 
hypothesis that chronic inflammation contributes to 
endothelial dysfunction [21]. Elevated serum levels of 
ET-1 have been shown to cooperate with other mark-
ers of endothelial activation, endothelial dysfunction, 
and low-grade chronic inflammation molecules. It was 
found that there is a relationship between ET-1 and hy-
perandrogenaemia [27].
Advanced glycation end products (AGEs) are pro-in-
flammatory molecules that trigger a  state of intracel-
lular oxidative stress and inflammation after binding 
to their cell membrane receptors RAGE [28]. In women 
with PCOS, the concentration of AGEs is increased, and 
it has a pathogenic significance in many complications. 
Reason for pathological changes of AGEs include acti-
vating oxidative stress and inflammation [29]. PCOS 
women have elevated serum/ovarian AGEs and ovarian 
RAGE women with PCOS have a  systemic chronic in-
flammatory condition even at the ovarian level, as rep-
resented by elevated levels of serum/ovarian AGEs and 
increased expression of the pro-inflammatory RAGE in 
ovarian tissue [30].
It has also been found that the insulin resistance 
of the arterial endothelial cells is associated with de-
creased synthesis of nitric oxide and increased synthe-
sis of vasoconstricting agents. This leads to increased 
vascular stiffness [14].
Endothelium dysfunction occurs at the beginning 
of the atherosclerotic process [31]. Measuring carotid 
intima-media thickness is a  non-invasive method for 
diagnosing atherosclerosis [32]. Carotid intima-media 
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thickness is a structural change in the vascular system 
visualised by ultrasonography, and it is a strong predic-
tor of cardiovascular events [33]. According to Arme-
ni et al., arterial stiffness is increased in women with 
PCOS. It might be a  mechanism through which PCOS 
increases the risk of CVD and hypertension [13].
In other research, which was conducted on young 
women with PCOS, early markers of atherosclerosis 
were studied using CVD markers assessed by ultraso-
nography, including: common carotid artery stiffness 
index and distensibility, and intima-media thickness. 
It was found that already in young age, women with 
PCOS exhibit changes in vascular elasticity even in the 
absence of classical risk factors for CVD, such as hyper-
tension and obesity [34]. Regarding the contribution of 
individual PCOS features, hyperandrogenism and in-
sulin resistance are the most significant predictors of 
arterial stiffness [13]. An attempt to explain the effects 
of hyperandrogenism on arterial stiffness is based on 
rats model – testosterone has influence on vascular 
contraction and interferes with oestradiol-mediated 
endothelium-dependent vasodilation [35]. Central arte-
rial stiffness is characterised by excessive collagen in 
the vessel wall, an amount higher than the presence 
of elastin, induced by the inflammatory state and the 
increase in luminal pressure. Metal-proteinases also 
play an important role in degrading the matrix protein. 
Moreover, the glycation phenomenon makes collagen 
more rigid, reduces elastin, and stimulates inflamma-
tion in vessels [36].
Hyperandrogenaemia in women with PCOS is asso-
ciated with an elevated blood pressure independently 
of the patient’s age, insulin resistance, obesity, and 
dyslipidaemia [37]. Furthermore, Markopoulos et al. 
performed a  study to examine hyperandrogenism in 
PCOS after menopause. They found that postmeno-
pausal PCOS women are exposed to higher adrenal and 
ovarian androgen levels than non-PCOS women [38]. 
Puurunen et al., based on the results of cross-sectional 
research, claimed that impaired glucose metabolism, 
increase ovarian androgen secretion, and chronic in-
flammation observed in premenopausal women with 
PCOS continue after their menopause [39]. In conclu-
sion, hyperandrogenaemia might increase the risk of 
hypertension in postmenopausal women with PCOS.
Ethinylestradiol in combined hormonal contracep-
tives elevates the production of hepatic angiotensino-
gen, which causes an elevation of blood pressure via 
the rennin–angiotensin–aldosterone system, regardless 
of the route of administration [40]. Despite the evolu-
tion of new progestogens, only drospirenone has the 
antimineralocorticoid activity of endogenous proges-
terone, regardless of the ethinylestradiol dose present 
in hormonal contraceptives [41]. Therefore, systolic 
arterial hypertension is considered an unfavourable 
effect of contraceptives. That is why the use of hor-
monal contraceptives is not indicated for women with 
hypertension with or without PCOS, regardless of the 
route of administration or oestrogen type [42]. In the 
other hand, in another study, it was found that lower-
ing androgen levels with a  combined oral contracep-
tive resulted in lower arterial stiffness over a period of 
12 months in women with PCOS [43]. In postmeno-
pausal women, oestrogen replacement therapy ame-
liorated hyperandrogenicity, and this was accompanied 
by marked improvements in glucose homeostasis and 
lipoprotein profile [44]. In another study, women who 
took hormone replacement therapy had higher SHBG, 
and lower FAI levels were noted among postmenopaus-
al women who developed CVD events [45].
Conclusions
Available studies show that women with PCOS more 
frequently present features of metabolic syndrome and 
have increased cardiovascular risk factors, including 
hypertension. Patients with this syndrome should be 
screened for these civilisation diseases and educated 
about the lifestyle modifications that could prevent hy-
pertension later in life [46, 47].
Further studies should broaden the knowledge con-
cerning dependency between PCOS, hypertension, and 
other civilisation diseases.
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